Patton Fund Management Inc. Raises Holdings in AbbVie Inc. $ABBV

Key Points

• Patton Fund Management ramped its stake in AbbVie by 740.6% in Q4 to 10,768 shares (worth ~$2.46M), while several large managers (Wellington, Raymond James, AllianceBernstein, Amundi) also markedly increased positions, leaving institutional ownership at about 70.23%.
• Positive catalysts include strong Phase 2 data for mirvetuximab (ELAHERE)
• Analysts show a consensus of "Moderate Buy" with an average target of $253 amid mixed price‑target moves; the stock trades below its 50/200‑day moving averages with a rich P/E (~87.5) and recent insider selling, though AbbVie yields ~3.4%.

Patton Fund Management Inc. grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 740.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,768 shares of the company's stock after buying an additional 9,487 shares during the quarter. Patton Fund Management Inc.'s holdings in AbbVie were worth $2,460,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ABBV. Wellington Management Group LLP lifted its holdings in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the period. Raymond James Financial Inc. increased its position in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock valued at $1,733,222,000 after buying an additional 2,753,312 shares in the last quarter. Alliancebernstein L.P. increased its position in AbbVie by 31.8% during the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock valued at $1,685,918,000 after buying an additional 1,758,657 shares in the last quarter. Amundi increased its position in AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after buying an additional 1,414,621 shares in the last quarter. Finally, Danske Bank A S acquired a new position in AbbVie during the 3rd quarter valued at about $279,609,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on ABBV. UBS Group reduced their target price on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They set an "overweight" rating and a $275.00 target price on the stock. Piper Sandler upped their target price on AbbVie from $289.00 to $299.00 and gave the company an "overweight" rating in a research report on Wednesday, February 18th. Finally, Morgan Stanley upped their target price on AbbVie from $269.00 to $270.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of "Moderate Buy" and an average target price of $253.00.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data for mirvetuximab soravtansine‑gynx (ELAHERE) in platinum‑sensitive ovarian cancer showed strong activity (objective response rate ~62.7% in FRα ≥50% patients) with consistent safety, supporting broader use across the ovarian cancer continuum and raising upside for AbbVie’s oncology franchise. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie struck an exclusive global license (ex-China/HK/Macau) with Haisco for two acute pain assets in a deal reported as up to roughly $715–745M, adding late‑stage pain programs and diversifying AbbVie’s pipeline outside its core immunology and oncology businesses. Haisco’s shares reacted positively. AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
• Positive Sentiment: An analyst raised AbbVie’s price target to $249, signaling bullish analyst sentiment that could support upside if execution on new indications and the pain franchise continues. AbbVie NYSE: ABBV Price Target Raised to $249.00
• Neutral Sentiment: Coverage notes (Zacks) flag neuroscience (Botox, Vraylar) as a growth driver for Q1 revenue, which could help offset legacy product declines but is already anticipated by the Street. Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
• Neutral Sentiment: Local reporting on an AbbVie Foundation donation to a university cancer center says the gift won’t affect clinical independence — largely a reputational/PR item rather than a financial driver. UCMed Administrators Say AbbVie Foundation Donation to New Cancer Center Will Not Infringe on Its Independence
• Negative Sentiment: Despite the positive data and deal news, the stock is trading lower—likely reflecting short‑term profit‑taking, stretched valuation (high P/E vs. peers) and technical pressure (shares below recent 50/200‑day moving averages), which can mute immediate upside. (Background market/technical context provided.)

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.06% of the company's stock.

AbbVie Stock Down 0.7%

AbbVie stock opened at $206.40 on Tuesday. The firm has a market cap of $364.94 billion, a price-to-earnings ratio of 87.46, a price-to-earnings-growth ratio of 0.75 and a beta of 0.38. The business's 50-day moving average price is $219.96 and its 200 day moving average price is $223.96. AbbVie Inc. has a 52 week low of $168.54 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts' expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business's revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie's dividend payout ratio (DPR) is 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.